Relationship between quality of life and survival in patients with pancreatic and periampullary cancer: A multicenter cohort analysis

Tara M. Mackay, Anouk E.j. Latenstein, Mirjam A.g. Sprangers, Lydia G. Van Der Geest, Geert-jan Creemers, Susan Van Dieren, Jan-willem B. De Groot, Bas Groot Koerkamp, Ignace H. De Hingh, Marjolein Y.v. Homs, Evelien J.m. De Jong, I. Quintus Molenaar, Gijs A. Patijn, Lonneke V. van de Poll-Franse, Hjalmar C. Van Santvoort, Judith De Vos-geelen, Johanna W. Wilmink, Casper H. Van Eijck, Marc G. Besselink, Hanneke W.m. Van Laarhoven_ _

Research output: Contribution to journalArticleScientificpeer-review


Patient-reported outcome measures (PROMs) are used increasingly in clinical practice to assess patients’ quality of life (QoL). Addressing QoL is important for patients with a short life expectancy, such as those with pancreatic and periampullary carcinoma, which has a median overall survival of 4 to 6 months.1 Different types of treatment that may improve survival in patients with pancreatic cancer may also impact QoL. Pancreatic resection has been found to be associated with a temporary deterioration in QoL, which usually returns to baseline values after 3 to 6 months.2,3 Moreover, chemotherapy has been found to improve QoL in randomized studies in the adjuvant and palliative setting.4,5

QoL may also be used to predict survival. Previous studies with other types of cancer (eg, breast, lung, esophageal, liver) consistently found a correlation between QoL and survival.6–11 Previous studies combined patients with different types of cancer, including a limited number (∼6%) of those with pancreatic cancer.9,10 Most of the data were acquired from randomized trials that included patients who were relatively fit. Only 1 case series of 55 patients with advanced pancreatic cancer suggested a prognostic relationship between the physical functioning scale scores of the EORTC Quality of Life Questionnaire-Core 30 (QLQ-C30) and survival.12

In the Netherlands, the Dutch Pancreatic Cancer Project (PACAP) was established in 2013. This is a multicenter cohort of patients with pancreatic and periampullary carcinoma for whom clinical data and PROMs are collected.13 We used this cohort to investigate the relationship between QoL and survival in daily clinical practice. The aim of this study was to examine which domains of QoL are predictive of survival in patients with pancreatic and periampullary cancer.
Original languageEnglish
Pages (from-to)1354-1363
JournalJournal of the National Comprehensive Cancer Network
Issue number10
Publication statusPublished - 2020


Dive into the research topics of 'Relationship between quality of life and survival in patients with pancreatic and periampullary cancer: A multicenter cohort analysis'. Together they form a unique fingerprint.

Cite this